Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

6.9K
The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
6.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

4.0K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FGFR inhibitor resistance in cervical cancer: a role for integrin α2 and mTOR signalling.

Frontiers in cell and developmental biology·2026
Same author

PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.

Cell reports·2026
Same author

Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma".

The Journal of pharmacology and experimental therapeutics·2026
Same author

Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.

International journal of molecular sciences·2025
Same author

AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility.

Scientific reports·2025

Related Experiment Video

Updated: Mar 31, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

Dysregulated FGF signalling in neoplastic disorders.

Yasmine Tanner1, Richard P Grose1

  • 1Centre for Tumour Biology, Barts Cancer Institute - A CR-UK Centre of Excellence, Queen Mary University of London, London, ECM1 6BQ England, UK.

Seminars in Cell & Developmental Biology
|October 15, 2015
PubMed
Summary

Fibroblast growth factor (FGF) signaling drives cancer by altering cell functions. Understanding FGF pathway deregulation is key to developing targeted therapies for FGF receptor (FGFR)-driven cancers.

Keywords:
CancerCell signallingFibroblast growth factorFibroblast growth factor receptorNeoplastic disorders

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

5.2K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.8K

Related Experiment Videos

Last Updated: Mar 31, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

5.2K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Fibroblast Growth Factor (FGF) signaling regulates crucial cellular functions like proliferation, survival, differentiation, and migration.
  • FGF signaling is frequently dysregulated in cancer, providing growth and survival advantages to malignant cells.
  • Aberrations in FGF ligands, receptors, or regulatory molecules can drive cancer progression.

Purpose of the Study:

  • To review the mechanisms of FGF pathway deregulation in cancer.
  • To examine the prevalence of FGF pathway aberrations across various cancer types.
  • To discuss the progress in developing targeted therapies for FGF receptor (FGFR)-driven cancers.

Main Methods:

  • Review of existing literature on FGF signaling in cancer.
  • Analysis of genomic data highlighting alterations in the FGF network.
  • Examination of studies on targeted therapeutic approaches for FGFR-driven cancers.

Main Results:

  • FGF signaling plays a significant role in carcinogenesis through various mechanisms, including genetic alterations and stromal influences.
  • Genomic technologies have revealed mutations, amplifications, translocations, and losses within the FGF signaling network contributing to cancer.
  • Stromal cells also contribute to pro-tumorigenic effects via FGF signaling.

Conclusions:

  • Understanding the pro-tumorigenic effects of FGF signaling perturbations is crucial for developing effective cancer therapies.
  • Targeted therapies aimed at FGFR-driven cancers are advancing.
  • Further research into FGF deregulation mechanisms will inform future treatment strategies.